Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
148.00
-2.03 (-1.35%)
Streaming Delayed Price
Updated: 3:05 PM EST, Mar 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
March 02, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
February 25, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
February 23, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
February 23, 2026
From
Arcellx, Inc.
Via
Business Wire
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
February 17, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
February 10, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
February 10, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
February 06, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Crossroads4Hope Kicks Off Its 25th Year of Caring with the Launch of Free Breast and Colorectal Cancer Resources for Patients and Families Nationwide
February 02, 2026
Via
PRLog
The Commonwealth Club Honors Black History Month With Event Featuring Top Black Leaders in AI & Biopharma Discussing the Future of Healthcare
January 29, 2026
Via
Get News
Topics
Artificial Intelligence
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
January 27, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
January 21, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conference
December 22, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
December 22, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
December 19, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
December 18, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
December 15, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
December 12, 2025
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
December 09, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
December 07, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
December 06, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
December 06, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Foundation Commits Over $3 Million to Address Food Insecurity
November 24, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
November 18, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
November 13, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
GBK Brand Bar and Meals on Me Host the Official Backstage Lounge at the 40th Annual Rock & Roll Hall of Fame Induction Ceremony Rehearsals
November 10, 2025
November 10, 2025 -- During rehearsals leading up to the Induction Ceremony, GBK welcomed some of the world's biggest musicians from legendary icons to today's top superstars.
Via
24-7 Press Release
Gilead Provides Update on Phase 3 ASCENT-07 Study
November 07, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
November 07, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
November 04, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
November 03, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
